/

CRIS

Curis, Inc.Closed

0.6149−0.04 −6.21%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.6272 +2.00%

Open

0.6400

Prev close

0.6556

Day range

0.59100.6862

52-week range

0.591033.60

Volume

210.18K1.05×

Mkt cap

1.49M

P/E ttm

0.47

Fwd P/E

-0.10

EPS ttm

1.32

Div yield

0.00%

Earnings

—

From 52w high

−98.17%

Price Chart

Yahoo Finance · delayed

CRISOct 12, 2026O 0.6800H 0.6900L 0.6300C 0.6400−0.0300 (−4.48%)Vol 127.80K

SMA 501.6112
SMA 20010.3462

1Y change −97.89% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CRIS Curis, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −18.99%
1 month: −43.36%
3 months: −86.53%
6 months: −94.84%
Year to date: −96.77%
1 year: −97.89%

Valuation & ownership

Market cap: 1.49M
Enterprise value: −2.74M
P/E (ttm): 0.47
Forward P/E: -0.10
PEG ratio: —
Price / book: 0.26
Price / sales (ttm): 0.35
EV / EBITDA: 0.08
EPS (ttm): 1.32
EPS (forward): -6.01
Beta (5y monthly): 3.10
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 2.43M
Float: 1.84M
Short % of float: 7.46%
Short ratio (days): 1.20
Held by insiders: 6.46%
Held by institutions: 29.05%
Avg volume (3m): 200.28K
50-day average: 1.61
200-day average: 10.35
52-week change: −97.89%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 13.2
vs 50-day SMA: −60.28%
vs 200-day SMA: −93.81%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 19.58%
Realised vol (20d, ann.): 49.2%
From 52-week high: −98.10%
From 52-week low: +4.92%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

42.67

+6,838.80% implied

Low 20.00Median 43.00High 65.00

Recommendation trend

Now4 / 0 / 0
1m ago4 / 0 / 0

Buy / hold / sell counts

DES

About Curis, Inc.

Yahoo Finance profile

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 20
Headquarters: Lexington, MA, United States
Website: curis.com
Officers: Mr. James E. Dentzer President, CEO, Secretary, Treasurer & Director

SEAS

Seasonality · CRIS

2007–2026 · monthly returns

Strongest month Dec +21.69%Weakest month Oct −5.71%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-9.1	26.7	-51.8	9.1	-5.0	-8.8	-51.7	-70.3	-43.6	-26.8			−96.9%
2025	15.0	-14.8	-30.0	0.5	16.6	-5.7	-28.4	0.6	-0.6	-10.2	-8.1	-27.7	−67.6%
2024	-22.4	2.9	6.7	41.2	-32.5	-33.4	-20.6	0.9	-2.5	-20.6	2.6	-30.3	−76.0%
2023	32.7	-15.1	-3.2	43.3	-9.3	6.4	-3.6	-30.0	-41.2	-28.2	202.5	-10.9	+15.9%
2022	-33.0	5.0	-29.0	-61.8	-16.5	28.9	1.0	-2.0	-27.8	14.3	1.3	-32.1	−88.4%
2021	27.6	-5.8	15.0	-4.4	33.1	-44.0	-5.9	16.6	-11.5	-17.0	-24.9	-2.5	−41.9%
2020	-6.5	-18.2	-46.2	31.4	-8.7	44.0	-3.3	-6.0	6.4	-1.7	26.1	464.8	+381.8%
2019	69.6	-10.3	89.5	-5.5	-25.5	32.9	22.0	-15.4	16.7	1.8	-21.1	-5.6	+146.4%
2018	-11.4	-19.4	30.0	-18.5	4.9	-37.8	-9.2	8.3	4.7	-8.4	-47.2	-19.8	−80.3%
2017	-6.8	-19.5	20.3	-12.9	-29.3	10.5	3.2	4.6	-27.0	6.0	-49.4	-12.5	−77.3%
2016	-43.6	-16.5	17.5	24.2	-12.5	-10.9	7.7	4.8	48.3	-0.4	11.2	6.6	+5.8%
2015	22.7	67.4	-22.1	7.1	31.1	-1.8	-5.1	-16.6	-22.9	1.0	34.3	6.2	+94.0%
2014	0.4	7.8	-7.5	-19.9	-21.2	4.5	4.3	-9.8	-19.4	-7.1	13.0	1.4	−46.8%
2013	-7.3	-15.4	21.9	14.3	0.3	-15.2	30.1	5.5	1.8	-10.5	-19.8	-11.9	−17.8%
2012	5.8	-8.9	6.9	-0.6	-2.3	15.4	-10.4	-9.1	-5.9	-8.0	-12.1	2.4	−26.7%
2011	39.9	12.3	4.5	28.0	-9.6	-4.8	-2.5	-8.3	-1.3	16.5	-1.9	29.6	+136.4%
2010	-36.6	38.8	7.3	7.5	-4.5	-55.9	23.7	-28.5	11.4	2.2	20.0	17.9	−39.1%
2009	24.0	29.0	15.0	-15.2	24.8	9.6	-12.5	50.7	10.9	-15.0	31.2	24.5	+333.3%
2008	55.1	-4.6	-2.1	-2.1	7.2	-2.0	16.4	2.4	-33.9	-25.2	-16.3	4.2	−23.5%
2007	12.7	-2.1	9.4	36.2	-32.9	-15.8	0.9	-15.3	-2.0	2.0	-9.0	7.7	−22.2%

INSD

Insider Activity · CRIS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

370K shares

Sells, 6 months

95.2K shares

Net shares

+274.8K

Net change in insider shares

−196.40%

Date	Insider	Transaction	Shares	Value
Mar 30, 2026	Kaitin Kenneth IDirector	Purchase at price 0.55 per share.	10K	$5.49K
Mar 19, 2026	Dentzer James EChief Executive Officer	—	133.3K	—
Mar 19, 2026	Rubin Marc RDirector	—	26.7K	—
Mar 19, 2026	Hamdy AhmedOfficer	—	66.7K	—
Mar 19, 2026	Duvall DianthaChief Financial Officer	—	66.7K	—
Mar 19, 2026	Zung Jonathan B Ph.D.Officer	—	66.7K	—

13F

Investors Holding CRIS

latest 13F filings of 29 followed managers

Investors holding CRIS
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$74.1K	0.00%	141.97K	−61%	Q2 2026
Maverick Capital · Lee Ainslie	$6.2K	0.00%	49.55K	—	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CRIS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CRIS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Curis, Inc.

Seasonality · CRIS

Insider Activity · CRIS

Congress Trades · CRIS

Investors Holding CRIS

Investors Holding CRIS

Congress Trades · CRIS

Insider Activity · CRIS

Seasonality · CRIS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Curis, Inc.

Financial Snapshot

Earnings & Dividends

News